Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma

Figures & data

Table 1 Clinical Characteristics of NPC Patients with Pulmonary and/or Hepatic Metastasis

Characteristic
Age (yr)
Median	48
Range	23–67
Sex, n (%)
Male	34 (82.9)
Female	7 (17.1)
Non-keratinizing, n (%)
Undifferentiated type	37 (90.2)
Differentiated type	4 (9.8)
Site of metastasis, n (%)
Lung	15 (36.6)
Liver	9 (22.0)
Multiple locations	17 (41.4)
Treatment line
Second-line	17 (41.4)
Third-line	20 (48.8)
Fourth-line	4 (9.8)
Previously received IMRT, n (%)
Yes	33 (80.5)
No	8 (19.5)
EB DNA*, n (%)
≥5.0E+2 copies/mL	32 (78.0)
<5.0E+2 copies/mL	9 (22.0)

Notes: *EBV DNA copy number was detected by real-time polymerase chain reaction (PCR).

Table 2 Most Common Toxicities Observed During Treatment

Toxicity, n	Grade
	I	II	III	IV	Sum (%)
Hypertension	7	5	1	0	13 (31.7)
Proteinuria	1	1	0	0	2 (4.9)
Fatigue	6	2	1	0	9 (21.9)
Hepatic insufficiency	1	0	0	0	1 (2.4)
Mucositis	4	1	0	0	5 (12.2)
Myelosuppression	7	1	2	0	10 (24.4)
Hand-foot syndrome	5	2	0	0	7 (17.1)
Loss of appetite	8	8	0	0	16 (39.0)
Dyslipidemia	9	3	2	0	14 (34.1)
Dizziness	3	0	0	0	3 (7.3)
Hoarseness	1	0	0	0	1 (2.4)

Figure 1 Kaplan–Meier estimate of PFS for Chinese NPC patients with pulmonary and/or hepatic metastasis treated with low-dose apatinib plus S-1.

Figure 2 Kaplan–Meier estimate of OS for Chinese NPC patients with pulmonary and/or hepatic metastasis treated with low-dose apatinib plus S-1.